Background: In the last years (18)F-FDG-positron-emission-tomography (PET) worked satisfactorily as helpful auxiliary method in order to verify recurrency of head and neck tumors and to detect primary tumors in case of CUP syndrome especially when CT and MR imaging failed to identify the tumor accurately. Fusion of FDG hypermetabolism in PET scan and anatomical structures is achieved by integrating positron emission tomography with CT and provides improvement also in case of CUP syndrome. This retrospective study shows 47 patients with neck metastases where PET or PET/CT helped to detect primary tumor site.
Patients: In a retrospective investigation 49 PET studies of 47 patients with CUP syndrome were analyzed.
Results: 9 cases had positive PET findings, 1 case false-positive. 5 cases were false-negative. In 40 PET studies there couldn't be found any sign of suspicious FDG hypermetabolism.
Conclusion: PET and PET/CT deliver a certain improvement in localization of primary tumor site and therapeutical strategy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2006-925297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of tea consumption with all-cause/cardiovascular disease mortality in the chronic kidney disease population: an assessment of participation in the national cohort.
Ren Fail
December 2025
State Key Laboratory of Traditional Chinese Medicine Syndrome, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: While there are numerous benefits to tea consumption, its long-term impact on patients with chronic kidney disease (CKD) remains unclear.
Method: Our analysis included 17,575 individuals with CKD from an initial 45,019 participants in the National Health and Nutrition Examination Survey (NHANES) (1999-2018). Individuals with extreme dietary habits, pregnancy, or non-CKD conditions were excluded.
Shifting from axillary dissection to targeted axillary surgery after neoadjuvant treatment: the evolving management of occult breast cancer in a monoinstitutional series of 114 patients.
Breast Cancer Res Treat
January 2025
Division of Breast Surgery, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Purpose: The use of neoadjuvant systemic therapy for primary breast cancer can achieve tumor shrinkage, enabling less invasive surgical treatments, such as breast-conserving surgery instead of mastectomy, and sentinel node biopsy instead of axillary dissection. In recent years, an increasing number of studies have explored the use of primary systemic therapy for occult breast cancer with axillary presentation. These studies suggest that a more conservative approach, involving targeted axillary surgery could be cautiously proposed for occult breast cancer after neoadjuvant chemotherapy in selected patients.
View Article and Find Full Text PDFSecond-Generation Antipsychotics Induce Metabolic Disruption in Adipose Tissue-Derived Mesenchymal Stem Cells Through an aPKC-Dependent Pathway.
Cells
December 2024
Department of Translational Medicine, Centre of Excellence in Aging Sciences, University of Piemonte Orientale, 28100 Novara, Italy.
Metabolic syndrome (MetS) is a cluster of metabolic abnormalities, including visceral obesity, dyslipidemia, and insulin resistance. In this regard, visceral white adipose tissue (vWAT) plays a critical role, influencing energy metabolism, immunomodulation, and oxidative stress. Adipose-derived stem cells (ADSCs) are key players in these processes within vWAT.
View Article and Find Full Text PDFPimozide Inhibits Type II but Not Type I Hair Cells in Chicken Embryo and Adult Mouse Vestibular Organs.
Biomedicines
December 2024
Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.
Background: Pimozide is a conventional antipsychotic drug of the diphenylbutylpiperidine class, widely used for treating schizophrenia and delusional disorders and for managing motor and phonic tics in Tourette's syndrome. Pimozide is known to block dopaminergic D2 receptors and various types of voltage-gated ion channels. Among its side effects, dizziness and imbalance are the most frequently observed, which may imply an effect of the drug on the vestibular sensory receptors, the hair cells.
View Article and Find Full Text PDFCAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?
BioDrugs
January 2025
Rheumatology Department, Strasbourg University Hospital, 1 Avenue Molière, 67000, Strasbourg, France.
Chimeric antigen receptor (CAR) T-cell therapy, initially successful in treating hematological malignancies, is emerging as a potential treatment for autoimmune diseases, including rheumatic conditions. CAR T cells, engineered to target and eliminate autoreactive B cells, offer a novel approach to managing diseases like systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myopathies, where B cells play a pivotal role in disease pathology. Early case reports have demonstrated promising results, with patients achieving significant disease remission, normalization of serological markers, and the ability to discontinue traditional immunosuppressive therapies, which supported the initiation of several clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!